Health Canada Issues recall of JAMP Pharma`s Rabeprazole
A week after the Centre banned the manufacturing, sale and distribution of 328 fixed dose combination (FDCNSE -1.81 %) drugs, Indian pharma major WockhardtNSE 7.53 % Friday moved the Delhi High Court against the Health Ministry's decision. The petition by Wockhardt was mentioned before a bench of Justices S Ravindra Bhat and A K Chawla, which allowed it to be listed for hearing today.
A decisive push by the Chinese government to root out polluting industries across the country is sending shock waves through the Indian pharmaceutical sector that depends heavily on active pharmaceutical ingredients (APIs) imported from China. The price of some APIs -- raw materials required for making finished drugs -- has gone up by around 40 per cent in the last four months in the Indian market and drug manufacturers, especially small and medium enterprises (SMEs), are struggling to fulfill their contractual obligations owing to steep rise in production cost, it is learnt.
Alkem Labs Generic Rabeprazole Sodium Receives Approval In US
Enforcement Report - Week of May 10, 2017
This new investment comes after the completion in early 2016 of a new CTD2 facility for the handling (development / manufacturing) of oral solid dosage Drug Product manufacturing of Highly Potent & Oncology compounds in its CordenPharma Plankstadt (Germany) facility, along with further expansion of capabilities in handling sterile Oncology Drug Products at CordenPharma Latina (Italy).
The nationwide law firm of Bernstein Liebhard LLP has launched a new Nexium lawsuit investigation, following the publication of two studies which found that the use of proton pump inhibitors may be associated with an increased risk of chronic kidney disease and kidney failure. The Firm is now offering free, no-obligation legal reviews to anyone who was diagnosed with serious kidney complications, including kidney disease, renal failure or acute interstitial nephritis, following treatment with Nexium or other proton pump inhibitors.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015.
Breckenridge`s Generic Rabeprazole Sodium approved in US for Gastric Ulcer
Breckenridge Pharmaceutical, Inc. announces the final approval by the U.S. Food and Drug Administration of the Abbreviated New Drug Application for Rabeprazole Sodium Delayed Release Tablets. The product is being manufactured and supplied by Rubicon Research Private Limited, and will be available in 20mg strengths and pack sizes of 30's, 90's and 500ct. Rabeprazole DR Tablets are AB rated to Aciphex®, which is indicated for the treatment, healing and maintenance of GERD in Adults and Adolescent Patients 12 Years of age and older and the healing of Duodenal Ulcers in Adults has annual sales of $128 million based on IMS Health sales data, as of September 2015. The product launch plans are being finalized and the first shipment will occur shortly.